By Dr Maya Kansara

Book Chapters

Lin FP; Tran M; Thavaneswaran S; Grady JP; Kansara M; Chan J; Ballinger ML; Simes J; Thomas DM, 2025, 'Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language Models', in , pp. 248 - 252, http://dx.doi.org/10.3233/SHTI250839

Journal articles

Kong BY; Lin FP-Y; Espinoza D; Aberoumand M; Thavaneswaran S; Meniawy T; Desai J; Harrup R; Nayagam SS; Charakidis M; Cuff K; Sebastian L; Lee CK; Wheeler P; Kansara M; Grady JP; Thomas DM; Ballinger ML; Simes J; Goldstein D, 2026, 'Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplifications: a molecular screening and therapeutics (MoST) program substudy', npj Precision Oncology, http://dx.doi.org/10.1038/s41698-026-01590-z

McNamee N; Aref A; Poulos R; Craft G; Koh J; Xavier D; Singh A; Kansara M; Robinson P; Hains P; Ballinger M; Liu JJ; Thomas D; Reddel R, 2026, 'Abstract B051: Targeted proteomics for parallel ADC biomarker screening: a pilot feasibility study within an Australian precision oncology program', Clinical Cancer Research, 32, pp. b051 - b051, http://dx.doi.org/10.1158/1557-3265.d32026-b051

Kok PS; Chan B; Aberoumoud M; Zhang A; O’Byrne K; Thavaneswaran S; Lin F; Kansara M; Corpuz T; Wheeler P; Simes RJ; Thomas D; Lee CK, 2026, 'Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma', Jto Clinical and Research Reports, 7, http://dx.doi.org/10.1016/j.jtocrr.2026.101014

Lin FP; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Desai J; Zaheed M; Chinchen S; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Mersiades A; Millward M; Brown MP; Charakidis M; Pokorny AMJ; Craft P; Espinoza D; Grimison P; Harrup R; Joshua AM; O'byrne K; Lee CK; Cowley MJ; Ballinger ML; Simes J; Thomas DM, 2026, 'Genomic Therapy Matching in Rare and Refractory Cancers', JAMA Oncology, 12, pp. 458 - 467, http://dx.doi.org/10.1001/jamaoncol.2026.0127

Koh B; Thavaneswaran S; Lin F; Grady J; Maddula M; Haghighi KS; Kansara M; Huang ML; Ballinger ML; Simes J; Thomas DM; Goldstein D, 2026, 'Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation', JCO Precision Oncology, 10, http://dx.doi.org/10.1200/PO-25-01003

Thavaneswaran S; Lin F; Espinoza D; Grady J; Kok PS; Chinchen S; Pavlakis N; Andelkovic V; Charakidis M; Craft P; Brown M; Desai J; Lau P; Kansara M; Simes J; Thomas D, 2025, 'A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden', Npj Precision Oncology, 9, http://dx.doi.org/10.1038/s41698-025-01156-5

Thavaneswaran S; Sim HW; Grady J; Espinoza D; Huang ML; Lin F; McGrath M; Desai J; Charakidis M; Brown M; Kansara M; Simes J; Thomas D, 2025, 'A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyae339

Lin FP-Y; Goldstein D; Grady JP; Napier C; Thavaneswaran S; Pitiyarachchi O; Kansara M; Chantrill LA; Sjoquist K; Thornton K; Raina A; Magenau A; Simes J; Ballinger ML; Sharbeen G; Timpson P; Pajic M; Phillips P; Thomas DM, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.4120

Lin FP-Y; Huang ML; Grady JP; Thavaneswaran S; Kansara M; Napier C; Ballinger ML; Simes J; Thomas DM, 2025, 'Machine learning-based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. e13683 - e13683, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e13683

Kansara M; Lin FP; Thavaneswaran S; Huang ML; Tran M; Corpuz T; Lu J; Espinoza D; Chinchen S; Ballinger M; Grimison P; Andelkovic V; Dow EG; Desai J; Simes J; Thomas D, 2025, '2715P Phase II trial of tildrakizumab in treatment-refractory bone and soft tissue sarcomas', Annals of Oncology, 36, pp. s1447, http://dx.doi.org/10.1016/j.annonc.2025.08.3325

Kansara M; Thavaneswaran S; Lin FP; Kok P-S; Grady J; Thomas H; Corpuz T; Mundra P; Lu J; Ballinger M; Desai J; Harrup RA; Craft P; Charakidis M; O'Byrne KJ; Selva-Nayagam S; Millwar M; Grimiso P; Simes J; Thomas D, 2025, 'A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterations', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.08.2175

Lin FP; Itchins M; Chinchen S; Thavaneswaran S; Mersiades A; Aberoumand M; Nagrial A; Xu W; Takhar HS; Harrup RA; Desai J; Cummins M; Espinoza D; Kansara M; Yip S; Lee CK; Simes J; Solomon BJ; Pavlakis N; Thomas D, 2025, 'Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.08.1565

Kok PS; Chan B; Zhang A; O'byrne K; Aberoumoud M; Thavaneswaran S; Lin FP; Kansara M; Corpuz T; Wheeler P; Simes J; Thomas DM; Lee CK, 2025, 'Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.10.1018

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Deng F; Li Y; Yang B; Sang R; Deng W; Kansara M; Lin F; Thavaneswaran S; Thomas DM; Goldys EM, 2024, 'Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing', Nature Communications, 15, pp. 1818, http://dx.doi.org/10.1038/s41467-024-46001-8

Filipe EC; Velayuthar S; Philp A; Nobis M; Latham SL; Parker AL; Murphy KJ; Wyllie K; Major GS; Contreras O; Mok ETY; Enriquez RF; McGowan S; Feher K; Quek LE; Hancock SE; Yam M; Tran E; Setargew YFI; Skhinas JN; Chitty JL; Phimmachanh M; Han JZR; Cadell AL; Papanicolaou M; Mahmodi H; Kiedik B; Junankar S; Ross SE; Lam N; Coulson R; Yang J; Zaratzian A; Da Silva AM; Tayao M; Chin IL; Cazet A; Kansara M; Segara D; Parker A; Hoy AJ; Harvey RP; Bogdanovic O; Timpson P; Croucher DR; Lim E; Swarbrick A; Holst J; Turner N; Choi YS; Kabakova IV; Philp A; Cox TR, 2024, 'Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism', Advanced Science, 11, http://dx.doi.org/10.1002/advs.202307963

Vaghjiani VG; Cochrane CR; Jayasekara WSN; Chong WC; Szczepny A; Kumar B; Martelotto LG; McCaw A; Carey K; Kansara M; Thomas DM; Walkley C; Mudge S; Gough DJ; Downie PA; Peacock CD; Matsui W; Watkins DN; Cain JE, 2023, 'Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype', Oncogene, 42, pp. 3529 - 3541, http://dx.doi.org/10.1038/s41388-023-02864-7

Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0

Kansara M; Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.4093

Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Kansara M; Sebastian L; Kee D; Zaheed M; Millward M; Brown MP; Charakidis M; Craft PS; Grimison PS; Harrup RA; O'Byrne KJ; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.', Journal of Clinical Oncology, 41, pp. 1540 - 1540, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1540

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.5526

Thavaneswaran S; Mersiades A; Lin FP-Y; Espinoza D; Grady JP; Lee CK; Desai J; Brown MP; Grimison PS; O'Byrne KJ; Harrup RA; Nagrial A; Sebastian L; Chinchen S; Kansara M; Craft PS; Millward M; Simes J; Joshua AM; Thomas DM, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3127

Kansara M; Bhardwaj N; Thavaneswaran S; Xu C; Lee JK; Chang LB; Madison RW; Lin F; Hsu E; Patel VK; Aleshin A; Oxnard GR; Simes J; Nimeiri H; Thomas DM, 2023, 'Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab', Molecular Oncology, 17, pp. 298 - 311, http://dx.doi.org/10.1002/1878-0261.13349

Ballinger ML; Pattnaik S; Mundra PA; Zaheed M; Rath E; Priestley P; Baber J; Ray-Coquard I; Isambert N; Causeret S; van der Graaf WTA; Puri A; Duffaud F; Le Cesne A; Seddon B; Chandrasekar C; Schiffman JD; Brohl AS; James PA; Kurtz JE; Penel N; Myklebost O; Meza-Zepeda LA; Pickett H; Kansara M; Waddell N; Kondrashova O; Pearson JV; Barbour AP; Li S; Nguyen TL; Fatkin D; Graham RM; Giannoulatou E; Green MJ; Kaplan W; Ravishankar S; Copty J; Powell JE; Cuppen E; van Eijk K; Veldink J; Ahn JH; Kim JE; Lor Randall R; Tucker K; Judson I; Sarin R; Ludwig T; Genin E; Deleuze JF; Haber M; Marshall G; Cairns MJ; Blay JY; Thomas DM, 2023, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', Science, 379, pp. 253 - 260, http://dx.doi.org/10.1126/science.abj4784

Lin FP; Thavaneswaran S; Grady JP; Ballinger M; Kansara M; Oakes SR; Desai J; Lee CK; Simes J; Thomas DM, 2021, 'Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology', Npj Precision Oncology, 5, pp. 58, http://dx.doi.org/10.1038/s41698-021-00194-z

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, 38, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3073

Kansara M; Thomson K; Pang P; Dutour A; Mirabello L; Acher F; Pin JP; Demicco EG; Yan J; Teng MWL; Smyth MJ; Thomas DM, 2019, 'Infiltrating myeloid cells drive osteosarcoma progression via GRM4 regulation of IL23', Cancer Discovery, 9, pp. 1511 - 1519, http://dx.doi.org/10.1158/2159-8290.CD-19-0154

Kansara M; Teng MW; Smyth MJ; Thomas DM, 2014, 'Translational biology of osteosarcoma', Nature Reviews Cancer, 14, pp. 722 - 735, http://dx.doi.org/10.1038/nrc3838

Kansara M; Thomas DM, 2014, 'RB1-mediated cell-autonomous and hostdependent oncosuppressor mechanisms in radiation-induced osteosarcoma', Oncoimmunology, 3, http://dx.doi.org/10.4161/onci.27569

Kansara M; Leong HS; Lin DM; Popkiss S; Pang P; Garsed DW; Walkley CR; Cullinane C; Ellul J; Haynes NM; Hicks R; Kuijjer ML; Cleton-Jansen AM; Hinds PW; Smyth MJ; Thomas DM, 2013, 'Immune response to rb1-Regulated senescence limits radiation-Induced osteosarcoma formation', Journal of Clinical Investigation, 123, pp. 5351 - 5360, http://dx.doi.org/10.1172/JCI70559

Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD, 2013, 'Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer', Clinical Cancer Research, 19, pp. 5960 - 5971, http://dx.doi.org/10.1158/1078-0432.CCR-13-1337

Cain JE; McCaw A; Jayasekara WSN; Rossello FJ; Marini KD; Irving AT; Kansara M; Thomas DM; Ashley DM; Watkins DN, 2013, 'Sustained low-dose treatment with the Histone deacetylase inhibitor LBH589 induces terminal differentiation of osteosarcoma cells', Sarcoma, 2013, http://dx.doi.org/10.1155/2013/608964

Paget C; Duret H; Ngiow SF; Kansara M; Thomas DM; Smyth MJ, 2012, 'Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma', Oncoimmunology, 1, pp. 1313 - 1322, http://dx.doi.org/10.4161/onci.21680

Etemadmoghadam D; George J; Cowin PA; Cullinane C; Kansara M; Gorringe KL; Smyth GK; Bowtell DDL, 2010, 'Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer', Plos One, 5, http://dx.doi.org/10.1371/journal.pone.0015498

Kansara M; Tsang M; Kodjabachian L; Sims NA; Trivett MK; Ehrich M; Dobrovic A; Slavin J; Choong PFM; Simmons PJ; Dawid IB; Thomas DM, 2009, 'Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice', Journal of Clinical Investigation, 119, pp. 837 - 851, http://dx.doi.org/10.1172/JCI37175

Kansara M; Thomas DM, 2007, 'Molecular pathogenesis of osteosarcoma', DNA and Cell Biology, 26, pp. 1 - 18, http://dx.doi.org/10.1089/dna.2006.0505

Thomas D; Kansara M, 2006, 'Epigenetic modifications in osteogenic differentiation and transformation', Journal of Cellular Biochemistry, 98, pp. 757 - 769, http://dx.doi.org/10.1002/jcb.20850

Cullinane C; Dorow DS; Kansara M; Conus N; Binns D; Hicks RJ; Ashman LK; McArthur GA; Thomas DM, 2005, 'An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development', Cancer Research, 65, pp. 9633 - 9636, http://dx.doi.org/10.1158/0008-5472.CAN-05-2285

Morgan T; Atkins GJ; Trivett MK; Johnson SA; Kansara M; Schlicht SL; Slavin JL; Simmons P; Dickinson I; Powell G; Choong PFM; Holloway AJ; Thomas DM, 2005, 'Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor κB', American Journal of Pathology, 167, pp. 117 - 128, http://dx.doi.org/10.1016/S0002-9440(10)62959-8

Kansara M; Berridge MV, 2004, 'Oncogenes modulate cell sensitivity to apoptosis induced by glucose deprivation', Anticancer Research, 24, pp. 2503 - 2510

Kansara M; Berridge MV, 2004, 'Hemopoietic cell transformation is associated with failure to downregulate glucose uptake during the G2/M phase of the cell cycle', Experimental Cell Research, 293, pp. 321 - 330, http://dx.doi.org/10.1016/j.yexcr.2003.10.027

Ahmed N; Kansara M; Berridge MV, 1997, 'Acute regulation of glucose transport in a monocyte-macrophage cell line: Glut-3 affinity for glucose is enhanced during the respiratory burst', Biochemical Journal, 327, pp. 369 - 375, http://dx.doi.org/10.1042/bj3270369

Berridge MV; Tan AS; McCoy KD; Kansara M; Rudert F, 1996, 'CD95 (Fas/Apo-1)-induced apoptosis results in loss of glucose transporter function', Journal of Immunology, 156, pp. 4092 - 4099

Conference Papers

Cain JE; Cochrane CR; Vaghjiani V; Szczepny A; Mccaw A; Carey K; Martelotto L; Kansara M; Thomas D; Walkley C; Matsui WH; Watkins DN, 2018, 'p53 and RB regulate Hedgehog responsiveness via autophagy-mediated ciliogenesis', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-4994

Kansara M; Pang P; Sulkowski N; Teng M; Smyth M; Thomas D, 2018, 'Abstract PR13: Pivotal role of interleukin 23 in osteosarcoma development and its link with glutamate metabotropic 4: Identification of novel therapeutic targets for osteosarcoma', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. PR13 - PR13, http://dx.doi.org/10.1158/1557-3265.sarcomas17-pr13

Conference Abstracts

Southi N; Sim H-W; Grady J; Satgunaseelan L; Huang M; Kansara M; Yuile A; Zaman A; Lin F; Wheeler H; Hudson A; Ballinger ML; Thomas DM; Thavaneswaran S, 2025, 'PATH-52. Understanding the prevalence ofMTAP andCDKN2A/B deletion in gliomas by next generation sequencing', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v252 - v252, http://dx.doi.org/10.1093/neuonc/noaf201.1004

Thavaneswaran S; Espinoza D; Lin FP; Chinchen S; Kansara M; Ballinger M; Grady J; Grimison P; Millward M; Ladwa R; Joshua AM; Desai J; Simes J; Thomas D, 2025, 'Phase II trial of Vismodegib in advanced cancers with Hedgehog pathway alterations', in ANNALS OF ONCOLOGY, ELSEVIER, GERMANY, Berlin, Vol. 36, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), GERMANY, Berlin, 17 October 2025 - 21 October 2025, http://dx.doi.org/10.1016/j.annonc.2025.08.1542

Lin FPY; Grady JP; Napier CE; Callow M; Thavaneswaran S; Huang ML; Zaheed M; Kansara M; Sebastian L; Ballinger ML; Simes J; Thomas DM, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.', in Journal of Clinical Oncology, Vol. 42, pp. 1557 - 1557, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.1557

Back to profile page